Remdesivir-Induced Extreme Sinus Bradycardia in COVID-19

Mostrar otras versiones (1)

During the COVID-19 pandemic, there was an urgent need for any medication to help reduce the high death rate experienced during this deadly surge. Remdesivir is an FDA-approved drug for COVID-19 treatment, given its anti-inflammatory properties. Upon extensive literature search, we found two studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasef, Natale, Hamilton, Steven, Fatima, Tehreem, Osgood, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329595/
https://www.ncbi.nlm.nih.gov/pubmed/35910702
http://dx.doi.org/10.7759/cureus.27307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329595/
https://www.ncbi.nlm.nih.gov/pubmed/35910702
http://dx.doi.org/10.7759/cureus.27307

Ejemplares similares